1 |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 2010;25(9):603-5.
DOI
|
2 |
Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88.
DOI
|
3 |
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
DOI
|
4 |
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323(16):1574-81.
DOI
|
5 |
Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J 2020;55(5):2000547.
DOI
|
6 |
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020;382(25):e102.
DOI
|
7 |
Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020;31(8):1088-9.
DOI
|
8 |
Nikpouraghdam M, Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol 2020;127:104378.
DOI
|
9 |
Richardson S, Hirsch J, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323(20):2052-59.
DOI
|
10 |
Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran E, MacGowan A. Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect 2020;81(2):e59-e61.
DOI
|
11 |
Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 2003;139(9):715-23.
DOI
|
12 |
Hong KH, Choi JP, Hong SH, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax 2018;73(3):286-9.
DOI
|
13 |
Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 2005;41 Suppl 7:S504-S512.
DOI
|
14 |
Jin JM, Bai P, He W, et al. Higher severity and mortality in male patients with COVID-19 independent of age and susceptibility. Front Public Health 2020;8:152.
DOI
|
15 |
Hoffmann M, Kleine-weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-80.e8.
DOI
|
16 |
Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005;67(2):698-705.
DOI
|
17 |
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193-9.
DOI
|
18 |
Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6):623-8.
DOI
|
19 |
Patel S, Velkoska E, Burrell L. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol 2013;40(8):551-9.
DOI
|
20 |
Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv 2020:2020.03.04.20031120
|
21 |
Sharif M, Chitsazian Z, Moosavian M, et al. Immune disorders in hemodialysis patients. Iran J Kidney Dis 2015;9(2):84-96.
|
22 |
van Dijk P, Jager K, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001;16(6):1120-9.
DOI
|
23 |
Foley R, Parfrey P, Sarnak M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-S119.
DOI
|
24 |
Sarnak M, Jaber B. Mortality caused by sepsis in patients with endstage renal disease compared with the general population. Kidney Int 2000;58(4):1758-64.
DOI
|
25 |
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229):1054-62.
DOI
|
26 |
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934-43.
DOI
|
27 |
Schiffrin EL, Flack JM, Ito S, Muntner P, Wenn RC. Hypertension and COVID-19. Am J Hypertens 2020;33(5):373-4.
DOI
|
28 |
Knapp S. Diabetes and infection: Is there a link? - A mini-review. Gerontology 2013;59(2):99-104.
DOI
|
29 |
HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Available from https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHAstatement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp. Accessed May 8, 2020.
|
30 |
Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin 2016;31(1):81-4.
DOI
|
31 |
Geerlings S, Hoepelman A. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26(3-4):259-65.
DOI
|
32 |
Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020;41(19):1798-800.
DOI
|
33 |
Li B, Yang J, Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109(5):531-8.
DOI
|
34 |
Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
DOI
|
35 |
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):811-8.
DOI
|
36 |
Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9.
DOI
|
37 |
WHO. Coronavirus disease (COVID-19) situation dashboard. Available from https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd. Accessed August 27, 2020.
|
38 |
Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009;39(7):618-25.
DOI
|
39 |
Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(6):1304-9.
DOI
|
40 |
Leung JM, Tiew PY, Mac Aogain M, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology 2017;22(4):634-50.
DOI
|
41 |
Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003;8 Suppl:S9-14.
DOI
|
42 |
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12(7):6049-57.
DOI
|
43 |
WHO. Middle east respiratory syndrome coronavirus (MERSCoV). Available from https://www.who.int/emergencies/mers-cov/en/; 2019. Accessed Apr 9, 2020.
|
44 |
Torres-Salinas, D. Daily growth rate of scientific production on Covid-19. Analysis in databases and open access repositories. arXiv preprint arXiv:2004.06721.
|
45 |
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81(2):e16-e25.
DOI
|
46 |
Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021-8.
DOI
|